STOCK TITAN

Frankenius Equity swaps preferred for 759,000 TriSalus (TLSI) common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Frankenius Equity AB, a more than 10% holder of TriSalus Life Sciences, Inc., converted its entire Series A Convertible Preferred Stock into common shares. On July 31, 2025, it exchanged 230,000 preferred shares for 759,000 shares of common stock under a company exchange offer.

The offer calculates common shares using the liquidation preference of $10.00 per preferred share plus accrued and unpaid dividends through August 10, 2027, divided by a $4.00 conversion price per share. After the conversion, Frankenius Equity directly holds 6,989,748 TriSalus common shares, replacing its prior preferred position with ordinary equity.

Positive

  • None.

Negative

  • None.
Insider Frankenius Equity AB
Role null
Type Security Shares Price Value
Conversion Series A Convertible Preferred Stock 230,000 $0.00 --
Conversion Common Stock 759,000 $0.00 --
Holdings After Transaction: Series A Convertible Preferred Stock — 0 shares (Direct, null); Common Stock — 6,989,748 shares (Direct, null)
Footnotes (1)
  1. Represents shares received upon conversion of the Series A Preferred Stock (the "Preferred Stock") reported in Table II. Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share. On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer.
Common shares received 759,000 shares Common Stock received by Frankenius Equity on July 31, 2025
Preferred shares converted 230,000 shares Series A Convertible Preferred Stock converted into common
Conversion price $4.00 per share Formula divisor for calculating TriSalus common shares in the offer
Liquidation preference $10.00 per share Preferred share liquidation preference used in the exchange formula
Common shares after transaction 6,989,748 shares Frankenius Equity’s direct TriSalus common stock holdings post-conversion
Offer commencement date June 23, 2025 Date TriSalus began its preferred-for-common exchange offer
Dividend accrual end date August 10, 2027 End date for accrued and unpaid dividends in conversion formula
Series A Convertible Preferred Stock financial
"Represents shares received upon conversion of the Series A Preferred Stock"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
conversion price financial
"divided by a $4.00 conversion price per share"
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
liquidation preference financial
"equal to the sum of the liquidation preference per share price of $10.00"
A liquidation preference is a rule that determines who gets paid first and how much they receive when a company is sold, goes bankrupt, or distributes its assets. It gives certain investors a priority claim—often returning their original investment plus any agreed multiple—before other owners receive money, which shapes how much common shareholders and founders ultimately get; think of it as a front-of-the-line pass that affects payout order and investor returns.
accrued and unpaid dividends financial
"and all accrued and unpaid dividends per share outstanding through August 10, 2027"
Accrued and unpaid dividends are dividend payments that a company has declared or owes to shareholders but has not yet actually paid out. For investors this matters because it represents cash they expect to receive—like a paycheck that’s been earned but not yet issued—and signals the company’s payment priorities and short-term cash health, which can affect shareholder returns and claims in cases like restructuring.
Offer financial
"pursuant to an offer (the "Offer") the Company commenced on June 23, 2025"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Frankenius Equity AB

(Last)(First)(Middle)
BOX 984

(Street)
BORASV7SE-501 10

(City)(State)(Zip)

SWEDEN

(Country)
2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/31/2025C759,000(1)A$06,989,748D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A Convertible Preferred Stock$4(2)07/31/2025C230,000(3) (3) (3)Common Stock759,000$00D
Explanation of Responses:
1. Represents shares received upon conversion of the Series A Preferred Stock (the "Preferred Stock") reported in Table II.
2. Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share.
3. On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer.
Remarks:
/s/ Ulrika Joreteg04/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Frankenius Equity AB do in this TriSalus (TLSI) Form 4 filing?

Frankenius Equity AB converted all its TriSalus Series A Convertible Preferred Stock into common shares. It exchanged 230,000 preferred shares for 759,000 common shares on July 31, 2025, replacing its preferred stake with ordinary equity under a company exchange offer.

How many TriSalus (TLSI) common shares did Frankenius Equity receive?

Frankenius Equity received 759,000 TriSalus common shares. These shares came from converting 230,000 Series A Convertible Preferred Stock under an exchange offer, moving the investor from preferred securities into standard common equity in the company.

What happened to Frankenius Equity’s TriSalus (TLSI) preferred stock holdings?

All 230,000 shares of TriSalus Series A Convertible Preferred Stock held by Frankenius Equity were converted. After this transaction, its preferred stock position was reduced to zero, fully replaced by 759,000 newly issued common shares through the exchange offer.

How is the TriSalus (TLSI) preferred-to-common conversion price determined?

The conversion uses a formula based on a $10.00 liquidation preference plus accrued and unpaid dividends per preferred share through August 10, 2027. That total amount per share is divided by a $4.00 conversion price to calculate how many TriSalus common shares are issued.

How many TriSalus (TLSI) common shares does Frankenius Equity hold after the conversion?

After the conversion, Frankenius Equity directly holds 6,989,748 TriSalus common shares. This total reflects its position following the exchange of 230,000 preferred shares for 759,000 additional common shares under the company’s offer terms.

What company action enabled this TriSalus (TLSI) preferred stock conversion?

The conversion occurred pursuant to an offer TriSalus commenced on June 23, 2025. Under this offer, all holders of Series A Preferred Stock could exchange their preferred shares for common stock using the specified liquidation preference and $4.00 per-share conversion formula.